Introduction: The new category of chimeric antigen receptor T - cell raised hopes for a more effective treatment of large B cell lymphoma and acute lymphoblastic leukemia. Nevertheless, their soaring acquisition costs will stretch the fiscal capacity of the health systems worldwide. To this direction, the scope of this study is to provide a systematic review of their economic evaluations. Areas covered: A systematic review of the economic evaluations of tisagenlecleucel and axicabtagene was performed. Expert opinion: The available data indicate that these products demonstrate a potentially favorable cost-effectiveness ratio. Nevertheless, their budget impact is of overriding importance and it should be incorporated in any economic evaluation. Moreover, more affirmative clinical data are imperative in order to mitigate uncertainty.

中文翻译：

---

是奇美拉吗？ CAR-T细胞疗法的经济评估的系统回顾。


简介：新型嵌合抗原受体T细胞为更有效治疗大B细胞淋巴瘤和急性淋巴细胞白血病带来了希望。然而，它们不断飙升的采购成本将导致全球卫生系统的财政能力捉襟见肘。为此，本研究的范围是对其经济评估进行系统回顾。涵盖领域：对 tisagenlecleucel 和 axicabtagene 的经济评估进行了系统回顾。专家意见：现有数据表明，这些产品表现出潜在有利的成本效益比。然而，它们的预算影响至关重要，应纳入任何经济评估中。此外，为了减少不确定性，必须提供更多肯定的临床数据。